Development of specific vector containing FN-1 fused protein and SCCA promoter for esophageal cancer
食管癌FN-1融合蛋白和SCCA启动子特异性载体的研制
基本信息
- 批准号:14370370
- 负责人:
- 金额:$ 9.15万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2002
- 资助国家:日本
- 起止时间:2002 至 2003
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We screened several gene expressions in esophageal squamous cell carcinoma (ESCC) for the purpose of finding of cancer specific gene expression and development of therapeutic gene. Then we found that RCAS1 and caveolin-1 are potentially useful for the target of esophageal cancer. Subsequently, we constructed a shuttle vector to make adenoviral vectors in which SCCA2 promoter was introduced. An adenoviral vector which expresses proapoptotic gene KLAKLA2 driven by SCCA2 promoter was reconstructed. Ad-SCCAp-KLAKLAK induced apoptosis in SCCA2 producing cell lines LK2 and LC1, but not A549 or ABC-1 that did not produce SCCA2. Effects of gene therapy using Ad-SCCAp-KLAKLAK were observed in vivo SCCA2 producing tumors implanted on the hack of nude mice were successfully suppressed by Ad-SCCAp-KLAKLAK.
为了寻找食管鳞状细胞癌(ESCC)的特异性基因表达,开发治疗基因,我们对食管鳞状细胞癌(ESCC)中的几种基因表达进行了筛选。我们发现RCAS 1和caveolin-1可能是食管癌治疗的靶点。随后,我们构建了一个穿梭载体,使腺病毒载体中引入SCCA 2启动子。构建了由SCCA 2启动子驱动的表达促凋亡基因KLAKLA 2的腺病毒载体。Ad-SCCAp-KLAKLAK在产生SCCA 2的细胞系LK 2和LC 1中诱导凋亡,但在不产生SCCA 2的A549或ABC-1中不诱导凋亡。用Ad-SCCA_p-KLAKLAK在裸鼠皮下移植瘤中观察了Ad-SCCA_p-KLAKLAK的基因治疗效果。
项目成果
期刊论文数量(24)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nakakubo Y: "The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus"Cancer Letters. 177. 101-105 (2002)
Nakakubo Y:“食管鳞状细胞癌中 RCAS1 表达的预后意义”Cancer Letters。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Takahashi Y: "Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system"Experimental Cell Res. 293. 144-153 (2004)
Takahashi Y:“通过定量实时 RT-PCR 系统检测正常成人器官和未分化甲状腺癌细胞系中 39 个 HOX 基因的表达谱”实验细胞研究。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Cho Y: "CD4+ and CD8+ T Cells Cooperate to Improve Prognosis of Patients with Esophageal Squamous Cell Carcinoma."Cancer Res. 63. 1555-1559 (2003)
Cho Y:“CD4 和 CD8 T 细胞协同改善食管鳞状细胞癌患者的预后。”癌症研究。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hideaki Hashida: "Fusion of Tat protein transduction domain to poly-lysine as a new DNA delivery tool."British Journal of Cancer. 90. 1252-1258 (2004)
Hideaki Hashida:“Tat 蛋白转导结构域与聚赖氨酸的融合作为新的 DNA 传递工具。”英国癌症杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hashida H: "Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool"Br J Cancer. 90. 1252-1258 (2004)
Hashida H:“HIV-1 Tat 蛋白转导结构域与聚赖氨酸的融合作为新的 DNA 传递工具”Br J Cancer。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OKUSHIBA Shunichi其他文献
OKUSHIBA Shunichi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
ICF: A novel dual-target gene therapy for safe and efficacious treatment of chronic non-infectious uveitis
ICF:一种安全有效治疗慢性非感染性葡萄膜炎的新型双靶点基因疗法
- 批准号:
MR/Z50385X/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Research Grant
Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy
QbD 的下一代自动化和 PAT 实施以及细胞和基因治疗的增强方法
- 批准号:
10087446 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Collaborative R&D
Longitudinal structural and cognitive functional imaging and outcome prediction in focal epilepsy treated with gene therapy and surgical resection.
基因治疗和手术切除治疗局灶性癫痫的纵向结构和认知功能成像及结果预测。
- 批准号:
MR/X031039/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Research Grant
GeneT: The Gene Therapy CoE at the Center of Portugal
GeneT:葡萄牙中心的基因治疗 CoE
- 批准号:
10090933 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
EU-Funded
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
- 批准号:
MR/Y019458/1 - 财政年份:2024
- 资助金额:
$ 9.15万 - 项目类别:
Research Grant
SBIR Phase I: Development of an Adjustable Gene Therapy Platform Technology
SBIR 第一阶段:可调节基因治疗平台技术的开发
- 批准号:
2240683 - 财政年份:2023
- 资助金额:
$ 9.15万 - 项目类别:
Standard Grant
Exploration novel effects of SHED-TK-derived exosomes on TK/GCV suicide gene therapy
探索SHED-TK衍生的外泌体对TK/GCV自杀基因治疗的新作用
- 批准号:
23K15643 - 财政年份:2023
- 资助金额:
$ 9.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Gene expression profiling of skin ulcers for short-acting in vivo gene therapy
皮肤溃疡的基因表达谱用于短效体内基因治疗
- 批准号:
23K19673 - 财政年份:2023
- 资助金额:
$ 9.15万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Activation of long non-coding RNA by a gene therapy CRISPR/Cas9 approach to prevent vein graft failure
通过基因治疗 CRISPR/Cas9 方法激活长非编码 RNA 以预防静脉移植失败
- 批准号:
EP/X024563/1 - 财政年份:2023
- 资助金额:
$ 9.15万 - 项目类别:
Research Grant
Developing a gene therapy product to treat pressure ulcers in lower-limb amputees
开发一种基因治疗产品来治疗下肢截肢者的压力性溃疡
- 批准号:
2888189 - 财政年份:2023
- 资助金额:
$ 9.15万 - 项目类别:
Studentship